Abbott Laboratories (Pakistan) is a pharmaceutical company founded in 1888 that has been operating in Pakistan since 1948. It has over 1,500 employees and manufacturing facilities in Karachi. The company produces pharmaceuticals, nutritional products, diagnostics, and medical devices. Abbott's main competitors in Pakistan include GSK, Searle Pakistan, Sanofi Aventis, Ferozsons Labs, and Pfizer. An analysis of Abbott's strengths, weaknesses, opportunities, and threats was conducted, as well as financial analysis showing steady growth from 2012-2017. Recommendations included focusing on products with fewer side effects, reducing employee turnover, engaging with the government, and adopting new technologies.
Abbott is a global healthcare company founded in 1888 with headquarters in Chicago. It has expanded to over 150 countries with 74,000 employees. Abbott operates in pharmaceuticals, nutrition, diagnostics, and diabetes care. While it has a strong brand image and product quality, Abbott faces weaknesses such as slow production and centralized decision making. Opportunities include growing disease burdens and physician numbers. Threats are high inflation, political instability, and competitors. The analysis recommends Abbott focus on growth areas like heart medicines through advertising to address weaknesses and leverage strengths and opportunities.
Abbott laboratories pakistan (pvt) limitedFaraz Mehdi
This document provides an overview of Abbott Laboratories, a global healthcare company operating in over 130 countries. It discusses Abbott's vision, core values, product lines including pharmaceuticals, nutritionals, diagnostics and diabetes care. The document also includes Abbott Pakistan's background, SWOT analysis, financial performance from 2009-2006, and how profits were allocated in 2009. It states Abbott Pakistan is committed to continuing as a going concern with over Rs. 4.9 billion in assets in 2009.
This presentation is brief introduction of Pharma Market and work pattern of MNCs (GSK is taken as example).This presentation was given by Faheem Siddiqui in Entrepreneur Conference at MBBS campus-Dadu of Sindh University on 09th October-13
Sun Pharmaceuticals was founded in 1983 and has since grown to be one of the largest pharmaceutical companies globally through strategic mergers and acquisitions. Some of its most significant acquisitions include Ranbaxy Laboratories in 2014, which made it the largest pharmaceutical company in India. Sun Pharma focuses on generic and specialty drugs and generates most of its revenue from sales in the United States. It employs over 32,000 people worldwide and achieved $166 billion in revenue in 2013-2014 through its global manufacturing and distribution network. The company's leadership emphasizes the importance of speed, perfection, and building a strong team to drive continued growth.
Mergers and Acquisitions in Pharmaceutical Industry Anjali Makhijani
Mergers and acquisitions have impacted the pharmaceutical industry in several ways. They allow companies to expand their product portfolios and markets through acquiring complementary assets. However, they can also lead to job losses as companies consolidate. Major deals like Pfizer-Wyeth and Ranbaxy-Daichi Sankyo helped the companies strengthen their product pipelines but some deals negatively impacted R&D productivity and employee satisfaction in the long run. Overall, M&As in pharma aim to create shareholder value but often fail to achieve synergies.
The document discusses Novartis, a Swiss pharmaceutical company. It provides background on Novartis, including that it was created through a 1996 merger. It then discusses Novartis' case regarding an Indian patent, with timelines of key events from 1997 to 2009. Finally, it summarizes that Novartis spent very little (0.03%) of its Indian revenue on research and development in India, contradicting claims that restricting patents would reduce innovation.
competitive analysis of Abbott company.bilal hassan
Abbott Laboratories (Pakistan) is a pharmaceutical company headquartered in Karachi with manufacturing facilities in Landhi and Korangi. It has been operating in Pakistan since 1948 and has a presence in over 130 countries. The company generates annual revenue of PKR 26 billion with total assets of PKR 19 billion. Its main competitors include GSK, Searle Pakistan, Sanofi Aventis, Ferozsons Labs, Pfizer, and Getz. The pharmaceutical industry in Pakistan has grown significantly over the past decades but still needs more support to improve access to medicine for half the population.
Abbott is a global healthcare company founded in 1888 with headquarters in Chicago. It has expanded to over 150 countries with 74,000 employees. Abbott operates in pharmaceuticals, nutrition, diagnostics, and diabetes care. While it has a strong brand image and product quality, Abbott faces weaknesses such as slow production and centralized decision making. Opportunities include growing disease burdens and physician numbers. Threats are high inflation, political instability, and competitors. The analysis recommends Abbott focus on growth areas like heart medicines through advertising to address weaknesses and leverage strengths and opportunities.
Abbott laboratories pakistan (pvt) limitedFaraz Mehdi
This document provides an overview of Abbott Laboratories, a global healthcare company operating in over 130 countries. It discusses Abbott's vision, core values, product lines including pharmaceuticals, nutritionals, diagnostics and diabetes care. The document also includes Abbott Pakistan's background, SWOT analysis, financial performance from 2009-2006, and how profits were allocated in 2009. It states Abbott Pakistan is committed to continuing as a going concern with over Rs. 4.9 billion in assets in 2009.
This presentation is brief introduction of Pharma Market and work pattern of MNCs (GSK is taken as example).This presentation was given by Faheem Siddiqui in Entrepreneur Conference at MBBS campus-Dadu of Sindh University on 09th October-13
Sun Pharmaceuticals was founded in 1983 and has since grown to be one of the largest pharmaceutical companies globally through strategic mergers and acquisitions. Some of its most significant acquisitions include Ranbaxy Laboratories in 2014, which made it the largest pharmaceutical company in India. Sun Pharma focuses on generic and specialty drugs and generates most of its revenue from sales in the United States. It employs over 32,000 people worldwide and achieved $166 billion in revenue in 2013-2014 through its global manufacturing and distribution network. The company's leadership emphasizes the importance of speed, perfection, and building a strong team to drive continued growth.
Mergers and Acquisitions in Pharmaceutical Industry Anjali Makhijani
Mergers and acquisitions have impacted the pharmaceutical industry in several ways. They allow companies to expand their product portfolios and markets through acquiring complementary assets. However, they can also lead to job losses as companies consolidate. Major deals like Pfizer-Wyeth and Ranbaxy-Daichi Sankyo helped the companies strengthen their product pipelines but some deals negatively impacted R&D productivity and employee satisfaction in the long run. Overall, M&As in pharma aim to create shareholder value but often fail to achieve synergies.
The document discusses Novartis, a Swiss pharmaceutical company. It provides background on Novartis, including that it was created through a 1996 merger. It then discusses Novartis' case regarding an Indian patent, with timelines of key events from 1997 to 2009. Finally, it summarizes that Novartis spent very little (0.03%) of its Indian revenue on research and development in India, contradicting claims that restricting patents would reduce innovation.
competitive analysis of Abbott company.bilal hassan
Abbott Laboratories (Pakistan) is a pharmaceutical company headquartered in Karachi with manufacturing facilities in Landhi and Korangi. It has been operating in Pakistan since 1948 and has a presence in over 130 countries. The company generates annual revenue of PKR 26 billion with total assets of PKR 19 billion. Its main competitors include GSK, Searle Pakistan, Sanofi Aventis, Ferozsons Labs, Pfizer, and Getz. The pharmaceutical industry in Pakistan has grown significantly over the past decades but still needs more support to improve access to medicine for half the population.
Shaan Foods is a leading Pakistani manufacturer and exporter of packaged spices. The document provides an analysis of Shaan Foods including its history, products, target market, competitors like National Foods, and marketing strategies. It also includes a SWOT analysis, identifying strengths such as a variety of product lines and weaknesses like limited marketing campaigns. The analysis shows Shaan Foods has opportunities for international expansion while facing threats from competitors with stronger local distribution.
Abbott Laboratories is a large company based in Chicago that produces medical, pharmaceutical, and nutritional products. Their top-selling products include drugs for rheumatoid arthritis and epilepsy, coronary stents, and nutritional supplements. The company employs over 68,000 people globally and has been in business for over 120 years. Their vision focuses on innovation, quality, and customer trust. They face competition from large companies like Johnson & Johnson and must continually develop new products and technologies to remain competitive in their industry.
Sun Pharmaceutical Industries Ltd is an Indian multinational pharmaceutical company founded in 1983. It has grown to become the largest pharmaceutical company in India through acquisitions in the US and abroad. Some key points about Sun Pharma are that it went public in 1994, began exports in 1989, and ranked 5th largest pharmaceutical company in India by 2000. It has received several business leadership awards. The company has pursued growth through acquisitions and joint ventures globally. Its share price has risen in recent years and it remains one of the top contributors to key stock indices in India.
This investor presentation provides an overview of Sun Pharmaceutical Industries Ltd., including its strategy, history, business operations, research and development, and financials. The company has pursued a strategy of creating sustainable revenue streams through a focus on chronic therapies and cost leadership through vertical integration. It has grown significantly over the past 30 years through numerous acquisitions and a focus on key international markets like the US, Europe, and others. Sun Pharma has a strong presence in India and international generics markets as well as specialized API and finished dosage manufacturing facilities across four continents.
Shan Foods is a rapidly growing food company present in over 50 countries. It started 25 years ago from a single small room and has grown to become one of the largest exporters of premium quality packaged spices, recipe mixes, pickles, and desserts. Shan Foods is dedicated to ensuring consistent products through well-equipped production techniques and works with quality suppliers to diligently select the best quality spices.
GlaxoSmithKline (GSK) is a leading multinational healthcare company that has operated in Bangladesh for years. It focuses on developing, manufacturing, and commercializing pharmaceutical and consumer health products. GSK has leadership positions in several major therapeutic areas. Internally, GSK aims to create an engaging work environment for employees. It emphasizes learning, experience, and achieving business objectives. Externally, the pharmaceutical industry in Bangladesh is growing due to rising healthcare spending and support from the government. However, the industry also faces competition from local companies and other multinationals like GSK.
Pfizer Inc. is a Delaware corporation that was originally incorporated in 1942 as Chas. Pfizer & Co. Inc. Pfizer has since grown to be the largest pharmaceutical company in the world. The document outlines Pfizer's history from its founding in 1849, leadership structure, board of directors, product portfolio, market share and competitors. It also discusses Pfizer's corporate social responsibility initiatives and corporate governance policies.
This document provides an overview and analysis of Nestle company and its products in Pakistan. It begins with introductions and outlines Nestle's vision, mission, goals and objectives. It then provides a history of Nestle, describes its organizational hierarchy, and lists its main strategic business units related to milk products, beverages, prepared dishes, and chocolates. The document performs a marketing analysis and discusses Nestle's market positioning. It includes a questionnaire and highlights of Nestle's products. It then analyzes the marketing mix strategies for four key Nestle products: mineral water, Milkpak, noodles, and chocolates/juices. It also includes a BCG matrix and comparisons of Nestle's market growth and
Sun pharma- A complete company review, analysis of crisis and realistic recom...TilikaChawda
Sun pharma has been the most talked about Indian pharma company for being in the news several times for its unresolved issues with the US FDA regarding the Halol and Mohali plant.
This presentation has analysed the situation and it suggests various solutions for the same.
The document discusses the pharmaceutical industry and Pfizer's position as one of the largest companies in the sector, facing challenges from increasing competition, shorter patents, and the need to diversify beyond blockbuster drugs. It analyzes Pfizer's strengths in areas like research and development as well as opportunities for the company to move into new areas like medical devices, health insurance, and genetically modified foods.
This document analyzes Pfizer's strategic position and provides recommendations. It includes a SWOT analysis, noting strengths like Pfizer's brand image but also weaknesses like reliance on blockbuster drugs. Competitive analyses show Pfizer performs well but could improve research and development. The document recommends Pfizer focus on opportunities in emerging markets and growth areas through mergers and increasing R&D spending to develop new drugs. Various matrices are presented to evaluate strategies and recommend Pfizer pursue an integration or intensive strategy to capitalize on opportunities and strengths.
This document summarizes Pfizer's history and global operations. It traces the company's founding in 1849 and key developments, including mass producing citric acid in 1900, producing penicillin in the 1940s, and launching Viagra in 1998. It provides financial data and notes Pfizer's global sales distribution, international growth through foreign expansion and acquisitions. The document also describes Pfizer's global strategy of replacing expiring patents through R&D, intellectual property protection, and financial strategies to coordinate its worldwide pharmaceutical manufacturing, marketing and distribution networks.
This document summarizes the inventory management and supply chain processes of Shan Foods Pvt Ltd, a leading spice manufacturer in Pakistan. Shan Foods manages inventories of both finished goods and packaging materials using separate MRP systems. They have in-house warehouses located in major cities and over 150 vendors to ensure availability. Shan Foods implements just-in-time inventory management and material requirements planning to reduce costs and fulfill customer demand efficiently using forecasting and production scheduling. Their inventory management system tracks key metrics to optimize inventory levels and minimize related costs.
The document provides an overview of Pfizer Inc., including its business segments, geographic reach, goals, mission/values, history, strategy, external environment analysis, internal environment analysis, and recommendations. It analyzes Pfizer's pharmaceutical, animal health, and corporate/other business segments. Key points include Pfizer operating in over 150 countries, goals of growing in emerging markets and optimizing its patent-protected portfolio, and an analysis of its competitive environment and internal financial performance compared to rivals. One recommendation is for Pfizer to focus on emerging markets like Asia, China, and India.
Pfizer is a global pharmaceutical company with over $71 billion in combined revenue. It has over 100,000 employees working in over 150 countries. Pfizer has a diverse portfolio of over 60 products generating over $100 million in sales each and 16 products generating over $1 billion in sales. It focuses on key disease areas like neuroscience, oncology, and infectious diseases. Pfizer has a large research and development pipeline with over 600 projects in development and registration stages between its own pipeline and projects from its acquisition of Wyeth. Pfizer offers opportunities for challenging work and continuous learning for motivated individuals as part of its mission to improve health worldwide.
Pfizer is a large pharmaceutical company founded in 1849. In 2014, Pfizer's revenue was $53.8 billion with net income of $22 billion. Pfizer's top selling drugs include Lipitor, Lyrica, and Viagra. The company is evaluating strategic options to maintain its leadership position, including horizontal integration through an acquisition of AstraZeneca. In May 2014, Pfizer offered $117 billion for AstraZeneca, but the offer was rejected. Pfizer will likely need to make another major acquisition in the next 4-5 years to continue growing and remain the largest pharmaceutical company.
The document provides an overview of Sanofi, a major global pharmaceutical company, including:
- Its operations in over 100 countries with over 100,000 employees and 19,300 scientists
- Its business entities and therapeutic expertise in the Philippines, focusing on cardiovascular diseases, diabetes, oncology, and other areas
- Details on its organizational structure, vision and mission statements, research and development process, product types, supply chain, and performance in the diabetes drug category market
This document provides a strategic analysis of Pfizer, a major bio-pharmaceutical company. It begins with a brief history of Pfizer, founded in 1849, and its evolution from producing food ingredients and medicines during the Civil War to developing antibiotics like penicillin and pharmaceutical drugs. The document discusses Pfizer's current leadership and top competitors like Novartis, Merck, and AstraZeneca. It analyzes Pfizer's mission and vision statements according to best practices. Finally, it presents an external factor evaluation matrix to examine opportunities and threats in Pfizer's external environment, identifying technology advancement as a key external factor for the company.
Pfizer strategy for internationalizationAamir chouhan
This document provides an overview of Pfizer, a global pharmaceutical company. It discusses Pfizer's vision, mission, strategic moves, organizational structure, and key financial metrics. Pfizer discovers, develops, and markets prescription medicines for humans and animals. It has grown through acquisitions and partnerships, and restructured in 2014 to focus on innovative pharmaceuticals, vaccines, and consumer healthcare. Pfizer faces challenges from patent expirations and increasing costs of drug development.
SAYDON PHARAMACEUTICAL COMPANT in Pakistan.pptxQaziDildar1
This case study analyzes Saydon Pharma, a pharmaceutical company in Pakistan. It provides background on the pharmaceutical market and discusses Saydon's history, products, quality policies, marketing strategies, sales statistics, and SWOT analysis. Saydon has grown from 3 initial products to 121 current products distributed across 38 cities. It has received ISO certification and adheres to GMP standards. While it has a strong distribution network and market share in antibiotics, opportunities exist to expand product lines and address weaknesses in management and supply issues.
Shaan Foods is a leading Pakistani manufacturer and exporter of packaged spices. The document provides an analysis of Shaan Foods including its history, products, target market, competitors like National Foods, and marketing strategies. It also includes a SWOT analysis, identifying strengths such as a variety of product lines and weaknesses like limited marketing campaigns. The analysis shows Shaan Foods has opportunities for international expansion while facing threats from competitors with stronger local distribution.
Abbott Laboratories is a large company based in Chicago that produces medical, pharmaceutical, and nutritional products. Their top-selling products include drugs for rheumatoid arthritis and epilepsy, coronary stents, and nutritional supplements. The company employs over 68,000 people globally and has been in business for over 120 years. Their vision focuses on innovation, quality, and customer trust. They face competition from large companies like Johnson & Johnson and must continually develop new products and technologies to remain competitive in their industry.
Sun Pharmaceutical Industries Ltd is an Indian multinational pharmaceutical company founded in 1983. It has grown to become the largest pharmaceutical company in India through acquisitions in the US and abroad. Some key points about Sun Pharma are that it went public in 1994, began exports in 1989, and ranked 5th largest pharmaceutical company in India by 2000. It has received several business leadership awards. The company has pursued growth through acquisitions and joint ventures globally. Its share price has risen in recent years and it remains one of the top contributors to key stock indices in India.
This investor presentation provides an overview of Sun Pharmaceutical Industries Ltd., including its strategy, history, business operations, research and development, and financials. The company has pursued a strategy of creating sustainable revenue streams through a focus on chronic therapies and cost leadership through vertical integration. It has grown significantly over the past 30 years through numerous acquisitions and a focus on key international markets like the US, Europe, and others. Sun Pharma has a strong presence in India and international generics markets as well as specialized API and finished dosage manufacturing facilities across four continents.
Shan Foods is a rapidly growing food company present in over 50 countries. It started 25 years ago from a single small room and has grown to become one of the largest exporters of premium quality packaged spices, recipe mixes, pickles, and desserts. Shan Foods is dedicated to ensuring consistent products through well-equipped production techniques and works with quality suppliers to diligently select the best quality spices.
GlaxoSmithKline (GSK) is a leading multinational healthcare company that has operated in Bangladesh for years. It focuses on developing, manufacturing, and commercializing pharmaceutical and consumer health products. GSK has leadership positions in several major therapeutic areas. Internally, GSK aims to create an engaging work environment for employees. It emphasizes learning, experience, and achieving business objectives. Externally, the pharmaceutical industry in Bangladesh is growing due to rising healthcare spending and support from the government. However, the industry also faces competition from local companies and other multinationals like GSK.
Pfizer Inc. is a Delaware corporation that was originally incorporated in 1942 as Chas. Pfizer & Co. Inc. Pfizer has since grown to be the largest pharmaceutical company in the world. The document outlines Pfizer's history from its founding in 1849, leadership structure, board of directors, product portfolio, market share and competitors. It also discusses Pfizer's corporate social responsibility initiatives and corporate governance policies.
This document provides an overview and analysis of Nestle company and its products in Pakistan. It begins with introductions and outlines Nestle's vision, mission, goals and objectives. It then provides a history of Nestle, describes its organizational hierarchy, and lists its main strategic business units related to milk products, beverages, prepared dishes, and chocolates. The document performs a marketing analysis and discusses Nestle's market positioning. It includes a questionnaire and highlights of Nestle's products. It then analyzes the marketing mix strategies for four key Nestle products: mineral water, Milkpak, noodles, and chocolates/juices. It also includes a BCG matrix and comparisons of Nestle's market growth and
Sun pharma- A complete company review, analysis of crisis and realistic recom...TilikaChawda
Sun pharma has been the most talked about Indian pharma company for being in the news several times for its unresolved issues with the US FDA regarding the Halol and Mohali plant.
This presentation has analysed the situation and it suggests various solutions for the same.
The document discusses the pharmaceutical industry and Pfizer's position as one of the largest companies in the sector, facing challenges from increasing competition, shorter patents, and the need to diversify beyond blockbuster drugs. It analyzes Pfizer's strengths in areas like research and development as well as opportunities for the company to move into new areas like medical devices, health insurance, and genetically modified foods.
This document analyzes Pfizer's strategic position and provides recommendations. It includes a SWOT analysis, noting strengths like Pfizer's brand image but also weaknesses like reliance on blockbuster drugs. Competitive analyses show Pfizer performs well but could improve research and development. The document recommends Pfizer focus on opportunities in emerging markets and growth areas through mergers and increasing R&D spending to develop new drugs. Various matrices are presented to evaluate strategies and recommend Pfizer pursue an integration or intensive strategy to capitalize on opportunities and strengths.
This document summarizes Pfizer's history and global operations. It traces the company's founding in 1849 and key developments, including mass producing citric acid in 1900, producing penicillin in the 1940s, and launching Viagra in 1998. It provides financial data and notes Pfizer's global sales distribution, international growth through foreign expansion and acquisitions. The document also describes Pfizer's global strategy of replacing expiring patents through R&D, intellectual property protection, and financial strategies to coordinate its worldwide pharmaceutical manufacturing, marketing and distribution networks.
This document summarizes the inventory management and supply chain processes of Shan Foods Pvt Ltd, a leading spice manufacturer in Pakistan. Shan Foods manages inventories of both finished goods and packaging materials using separate MRP systems. They have in-house warehouses located in major cities and over 150 vendors to ensure availability. Shan Foods implements just-in-time inventory management and material requirements planning to reduce costs and fulfill customer demand efficiently using forecasting and production scheduling. Their inventory management system tracks key metrics to optimize inventory levels and minimize related costs.
The document provides an overview of Pfizer Inc., including its business segments, geographic reach, goals, mission/values, history, strategy, external environment analysis, internal environment analysis, and recommendations. It analyzes Pfizer's pharmaceutical, animal health, and corporate/other business segments. Key points include Pfizer operating in over 150 countries, goals of growing in emerging markets and optimizing its patent-protected portfolio, and an analysis of its competitive environment and internal financial performance compared to rivals. One recommendation is for Pfizer to focus on emerging markets like Asia, China, and India.
Pfizer is a global pharmaceutical company with over $71 billion in combined revenue. It has over 100,000 employees working in over 150 countries. Pfizer has a diverse portfolio of over 60 products generating over $100 million in sales each and 16 products generating over $1 billion in sales. It focuses on key disease areas like neuroscience, oncology, and infectious diseases. Pfizer has a large research and development pipeline with over 600 projects in development and registration stages between its own pipeline and projects from its acquisition of Wyeth. Pfizer offers opportunities for challenging work and continuous learning for motivated individuals as part of its mission to improve health worldwide.
Pfizer is a large pharmaceutical company founded in 1849. In 2014, Pfizer's revenue was $53.8 billion with net income of $22 billion. Pfizer's top selling drugs include Lipitor, Lyrica, and Viagra. The company is evaluating strategic options to maintain its leadership position, including horizontal integration through an acquisition of AstraZeneca. In May 2014, Pfizer offered $117 billion for AstraZeneca, but the offer was rejected. Pfizer will likely need to make another major acquisition in the next 4-5 years to continue growing and remain the largest pharmaceutical company.
The document provides an overview of Sanofi, a major global pharmaceutical company, including:
- Its operations in over 100 countries with over 100,000 employees and 19,300 scientists
- Its business entities and therapeutic expertise in the Philippines, focusing on cardiovascular diseases, diabetes, oncology, and other areas
- Details on its organizational structure, vision and mission statements, research and development process, product types, supply chain, and performance in the diabetes drug category market
This document provides a strategic analysis of Pfizer, a major bio-pharmaceutical company. It begins with a brief history of Pfizer, founded in 1849, and its evolution from producing food ingredients and medicines during the Civil War to developing antibiotics like penicillin and pharmaceutical drugs. The document discusses Pfizer's current leadership and top competitors like Novartis, Merck, and AstraZeneca. It analyzes Pfizer's mission and vision statements according to best practices. Finally, it presents an external factor evaluation matrix to examine opportunities and threats in Pfizer's external environment, identifying technology advancement as a key external factor for the company.
Pfizer strategy for internationalizationAamir chouhan
This document provides an overview of Pfizer, a global pharmaceutical company. It discusses Pfizer's vision, mission, strategic moves, organizational structure, and key financial metrics. Pfizer discovers, develops, and markets prescription medicines for humans and animals. It has grown through acquisitions and partnerships, and restructured in 2014 to focus on innovative pharmaceuticals, vaccines, and consumer healthcare. Pfizer faces challenges from patent expirations and increasing costs of drug development.
SAYDON PHARAMACEUTICAL COMPANT in Pakistan.pptxQaziDildar1
This case study analyzes Saydon Pharma, a pharmaceutical company in Pakistan. It provides background on the pharmaceutical market and discusses Saydon's history, products, quality policies, marketing strategies, sales statistics, and SWOT analysis. Saydon has grown from 3 initial products to 121 current products distributed across 38 cities. It has received ISO certification and adheres to GMP standards. While it has a strong distribution network and market share in antibiotics, opportunities exist to expand product lines and address weaknesses in management and supply issues.
Ranbaxy is India's largest pharmaceutical company with a global footprint in 43 countries. It has a diverse product portfolio and strong R&D capabilities. In 2011, Ranbaxy recorded global sales of $2.1 billion, with emerging and developed markets each contributing around 47% and 46% respectively. Ranbaxy aims to grow organically and inorganically, focusing on high-growth areas like biologics and injectables. It also has a hybrid business model through its alliance with Daiichi Sankyo to create an innovator and generic powerhouse. Ranbaxy emphasizes R&D as a strategic priority and has over 1,200 personnel dedicated to research.
Here are some key facts and figures about the global pharmaceutical industry:
- The global pharmaceutical market was estimated to be worth around $1.2 trillion in 2020. It is projected to reach $1.6 trillion by 2026.
- The top 10 global pharmaceutical companies by revenue in 2020 were Johnson & Johnson, Pfizer, Roche, Sanofi, Novartis, Merck & Co., AbbVie, GSK, Amgen, and Gilead Sciences.
- The top three pharmaceutical markets by sales in 2020 were the US at $360 billion, China at $145 billion, and Japan at $102 billion.
- The US accounted for around 40% of global pharmaceutical spending in 2020, despite
Ranbaxy Laboratories aims to become a research-based international pharmaceutical company. It has a strong presence in generics and is making progress in its drug discovery pipeline. Ranbaxy has grown organically and through acquisitions. It is India's largest pharmaceutical company and ranks 8th globally in generics. Ranbaxy continues to expand its global footprint and portfolio through strategic collaborations and alliances.
Catalent is the global leader in drug development and manufacturing. It has over 1,300 patents and is well-positioned to benefit from substantial industry growth of 6-10% annually through 2020. While pricing pressures could slow industry growth, Catalent's business model focusing on development, delivery, and supply solutions provides long-term stable revenues. The recommendation is to buy Catalent stock, which trades at $29.13 but has a target price of $35.99 based on discounted cash flow analysis.
The document provides an overview of Pfizer Inc., including its business segments, geographic reach, goals, mission/values, history, strategy, external environment analysis, internal environment analysis, and recommendations. It analyzes Pfizer's pharmaceutical, animal health, and corporate/other business segments. Key points include Pfizer operating in over 150 countries, goals of growing in emerging markets and optimizing its patent-protected portfolio, and an analysis of Pfizer's financial performance compared to rivals. One recommendation is for Pfizer to focus on emerging markets like Asia, China, and India.
Strategic management - An Outlook on Growth strategyNeha Kalal
Strategic management involves formulating, implementing, and evaluating cross-functional decisions to achieve organizational objectives. The key stages are strategy formulation, implementation, and evaluation. Strategy formulation involves determining the vision, mission, external/internal analysis to identify strengths, weaknesses, opportunities, and threats. Implementation establishes objectives, policies, motivation, and resource allocation. Evaluation assesses performance and makes corrections. Strategic planning provides financial and non-financial benefits but some firms do not plan due to lack of knowledge, poor structures, or overconfidence. Sun Pharma grew through strategic acquisitions of companies and plants from 1996-2015 to expand globally and into new therapy areas.
The pharmaceutical industry is the world's largest industry worth $2.8 trillion globally. The Indian pharmaceutical industry is the third largest by volume and exports 20% of generic drugs worldwide. It has grown significantly over the past two decades and is expected to become the sixth largest pharmaceutical market globally, worth $55 billion by 2020. The industry faces challenges of being highly fragmented, low profit margins due to government price controls, and low research and development investments due to pricing norms. The government is taking initiatives to support the industry through funding and reforms.
Presentation on PharmEvo - Karim Virani, Hina Tejani & Anila LakhaniKarim Virani
This document provides an overview of PharmEvo, a pharmaceutical company that is part of the Premier Group of Companies in Pakistan. It discusses PharmEvo's corporate profile, products, manufacturing facilities, distribution network, marketing strategies, and the pharmaceutical industry environment in Pakistan. Key points include that PharmEvo has over 1000 employees, annual turnover of over 2.5 billion rupees, and focuses on therapeutic areas like anti-infectives, gastroenterology, and cardiology. It manufactures various dosage forms and has facilities in Karachi. PharmEvo's distribution network relies on distributors and sub-distributors to reach customers across 34 cities in Pakistan.
This document provides an overview of Cipla Limited, an Indian pharmaceutical company. It discusses the company's history, vision, products, competitors, global presence, financial performance, SWOT analysis, and industry factors like PESTLE and Porter's Five Forces. Key points include that Cipla was founded in 1935 and is now a leading player in anti-infective and anti-asthmatic drugs. It has a presence in over 170 countries and 44 manufacturing facilities in India. A SWOT analysis identifies strengths like its product range and social initiatives, and weaknesses like a lack of presence in developed countries. PESTLE and Porter's Five Forces analyses examine political, economic, social and technological factors impacting the industry.
The document provides information about the 8th Asia Generics Conference taking place from 11-14 November 2013 in Singapore. The conference will discuss topics related to developing competitive strategies for pricing, portfolio management, and market access in the generics industry in Asia. It outlines an agenda with sessions on market outlook, regulatory pathways, market access opportunities, product differentiation, branding, distribution, and strategic partnerships. Speakers include representatives from Johnson & Johnson, Pfizer, Unilab, and other pharmaceutical companies. Workshops on go-to-market innovation and biosimilars entry are also advertised.
The document summarizes a research study conducted in Ahmedabad, India. The study aimed to understand the demand and supply of narcotic analgesic drugs (morphine, pethidine, fentanyl) in the city. It also sought to understand doctors' preferences for narcotic analgesics versus non-narcotic drugs, and hurdles faced by doctors and retailers in using and selling regulated narcotic drugs. The researcher administered questionnaires to anesthesiologists to understand demand, and retailers to understand supply. Most responding doctors preferred narcotic analgesics to non-narcotic drugs.
The document analyzes the Indian pharmaceutical industry. It discusses the industry value chain including R&D, manufacturing, marketing and distribution. It also outlines the key business verticals of APIs, formulations, biologics and clinical research. The domestic market is large and growing, valued at over $12 billion in 2013. Chronic therapies are growing faster than acute therapies due to lifestyle changes. Major players include domestic firms like Cipla, Sun and MNCs like GSK. Alliances and M&A are common as firms look to capitalize on the industry potential.
The document provides details about the 5th Biosimilars Congregation 2014 conference organized by Virtue Insight. It lists the key speakers from various pharmaceutical companies that will be speaking at the conference. The conference will discuss various topics related to biosimilars like clinical trials challenges, regulatory landscape, analytical strategies for biosimilarity, emerging market opportunities etc. It provides the agenda with session details, speaker bios and profiles. The document aims to invite attendees from pharmaceutical, biotech and regulatory organizations to attend and gain insights on biosimilars development and commercialization.
The document provides a market analysis for an analytics company called AlphaMD to enter the pharmaceutical market in the UAE. It includes a literature review on the pharmaceutical sector in UAE, identifying key parameters and needs of target companies through interviews. Based on a decision matrix, marketing pharmaceutical companies were identified as the top target. Recommendations include providing competitive intelligence and contracting services at affordable prices while maintaining quality. Limitations include lack of financial data from SMEs and limited interviews.
Similar a Competitive Analysis of Abbott Laboratories (20)
At Malayali Kerala Spa Ajman, Full Service includes individualized care for every client. We specifically design each massage session for the individual needs of the client. Our therapists are always willing to adjust the treatments based on the client's instruction and feedback. This guarantees that every client receives the treatment they expect.
By offering a variety of massage services, our Ajman Spa Massage Center can tackle physical, mental, and emotional illnesses. In addition, efficient identification of specific health conditions and designing treatment plans accordingly can significantly enhance the quality of massaging.
At Malayali Kerala Spa Ajman, we firmly believe that everyone should have the option to experience top-quality massage services regularly. To achieve that goal we offer cheap massage services in Ajman.
If you are interested in experiencing transformative massage treatment at Malayali Kerala Spa Ajman, you can use our Ajman Massage Center WhatsApp Number to schedule your next massage session.
Contact @ +971 529818279
Visit @ https://malayalikeralaspaajman.com/
Hypertension and it's role of physiotherapy in it.Vishal kr Thakur
This particular slides consist of- what is hypertension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is summary of hypertension -
Hypertension, also known as high blood pressure, is a serious medical condition that occurs when blood pressure in the body's arteries is consistently too high. Blood pressure is the force of blood pushing against the walls of blood vessels as the heart pumps it. Hypertension can increase the risk of heart disease, brain disease, kidney disease, and premature death.
Emotional and Behavioural Problems in Children - Counselling and Family Thera...PsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
As Mumbai's premier kidney transplant and donation center, L H Hiranandani Hospital Powai is not just a medical facility; it's a beacon of hope where cutting-edge science meets compassionate care, transforming lives and redefining the standards of kidney health in India.
Sectional dentures for microstomia patients.pptxSatvikaPrasad
Microstomia, characterized by an abnormally small oral aperture, presents significant challenges in prosthodontic treatment, including limited access for examination, difficulties in impression making, and challenges with prosthesis insertion and removal. To manage these issues, customized impression techniques using sectional trays and elastomeric materials are employed. Prostheses may be designed in segments or with flexible materials to facilitate handling. Minimally invasive procedures and the use of digital technologies can enhance patient comfort. Education and training for patients on prosthesis care and maintenance are crucial for compliance. Regular follow-up and a multidisciplinary approach, involving collaboration with other specialists, ensure comprehensive care and improved quality of life for microstomia patients.
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdfVedanta A
Air Ambulance Services In Rewa works in close coordination with ground-based emergency services, including local Emergency Medical Services, fire departments, and law enforcement agencies.
More@: https://tinyurl.com/2shrryhx
More@: https://tinyurl.com/5n8h3wp8
NURSING MANAGEMENT OF PATIENT WITH EMPHYSEMA .PPTblessyjannu21
Prepared by Prof. BLESSY THOMAS, VICE PRINCIPAL, FNCON, SPN.
Emphysema is a disease condition of respiratory system.
Emphysema is an abnormal permanent enlargement of the air spaces distal to terminal bronchioles, accompanied by destruction of their walls and without obvious fibrosis.
Emphysema of lung is defined as hyper inflation of the lung ais spaces due to obstruction of non respiratory bronchioles as due to loss of elasticity of alveoli.
It is a type of chronic obstructive
pulmonary disease.
It is a progressive disease of lungs.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
The Importance of Black Women Understanding the Chemicals in Their Personal C...bkling
Certain chemicals, such as phthalates and parabens, can disrupt the body's hormones and have significant effects on health. According to data, hormone-related health issues such as uterine fibroids, infertility, early puberty and more aggressive forms of breast and endometrial cancers disproportionately affect Black women. Our guest speaker, Jasmine A. McDonald, PhD, an Assistant Professor in the Department of Epidemiology at Columbia University in New York City, discusses the scientific reasons why Black women should pay attention to specific chemicals in their personal care products, like hair care, and ways to minimize their exposure.
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...DrDevTaneja1
Digital India will need a big trained army of Health Informatics educated & trained manpower in India.
Presently, generalist IT manpower does most of the work in the healthcare industry in India. Academic Health Informatics education is not readily available at school & health university level or IT education institutions in India.
We look into the evolution of health informatics and its applications in the healthcare industry.
HIMMS TIGER resources are available to assist Health Informatics education.
Indian Health universities, IT Education institutions, and the healthcare industry must proactively collaborate to start health informatics courses on a big scale. An advocacy push from various stakeholders is also needed for this goal.
Health informatics has huge employment potential and provides a big business opportunity for the healthcare industry. A big pool of trained health informatics manpower can lead to product & service innovations on a global scale in India.
The facial nerve, also known as cranial nerve VII, is one of the 12 cranial nerves originating from the brain. It's a mixed nerve, meaning it contains both sensory and motor fibres, and it plays a crucial role in controlling various facial muscles, as well as conveying sensory information from the taste buds on the anterior two-thirds of the tongue.
3. Contents
Industry & Company Profile and Key People
Competitors
IFE and EFE
CPM
Portor’s Five Forces
Financial Analysis
Recommendations & Conclusion
4. Industry Overview
• Pakistan Pharmaceutical Manufacturers’ Association
• In 1947, hardly any pharma industry.
• Now, 759 pharma manufacturing units + 25
multinational brands.
• Approx. meet 70% country demand.
• 2007 pharma’s sold were US$1.4bn.
• Despite good growth in last decade, about half of the
population have no access to modern medicine.
• Need more work from Govt. and Industry Stakeholders.
Pharma Link
5. Company Profile
Location
Head Office
Opposite Radio Pakistan
Transmission Center HYD
Road, Karachi
Products
1. Pharmaceuticals
2. Nutritional
3. Diagnostics
4. Medical Devices
Financial Facts
Revenue ▲PKR 26,088,233
(in ‘000) 2017
Total assets ▲PKR 19,236,259
(in ‘000) 2017
Board of Directors
Munir A. Shaikh (Chairman)
Syed Anis Ahmed (CEO)
Jamshed Azhar (CFO)
Rana A. Latif (Dir. Operations)
6.
7. Company Profile
Started in 1888 by Dr.
Wallace C. Abbott
1948 started in Pakistan
Now, Business in 130+
countries
Employees 1500
Manufacturing
Facilities at Landhi
and Korangi, Karachi
All top Pharma
Companies are
competitors
2nd largest market
share
Share Value = PKR
665.70 (PKR 5 Δ)
9. Company Profile
• Following are the main distributes of
Abbott:
• Premier Agency Muslimabad, Karachi
• Babar Medicine, Lahore
• Nadeem Traders, Peshawar.
• Baloch Enterprise, Multan
• D.S Pharma, Rawalpindi.
11. GSK is leading Pharma company of Pakistan and world’s 2nd largest
company. It was formed in 2001 after the merger of SmithKline,
Beecham (Pakistan) Limited and Glaxo Wellcome (Pakistan)
Limited. The present employees are about 2,000 and manages 150
brands.
The SEARLE Company Ltd (TSCL) incorporated in
Pakistan in 1965 as a subsidiary of G.D. Searle & Co.,
U.S.A. Today, Searle is ranked as 4th leading
pharmaceutical company in Pakistan. TSCL is
manufacturing organization of branded generics and
providing best research products in services of mankind.
Sanofi-aventis Pakistan limited ("Sanofi") is a patient-centric
company with over 1000 employees working every day with the
commitment to improve health and wellness across the country.
Sanofi ranks amongst the top ten pharmaceutical firms in Pakistan.
12. Ferozsons Laboratories founded in 1960. Ferozsons has market
leader brands in the areas of gastroenterology, hepatology,
cardiology and oncology, with an emerging presence in
endocrinology as well as mother and child health the diabetes spa.
Pfizer Pakistan has been working for the health and
well-being of people in Pakistan since 1959. Pfizer’s
Pakistan owns the livelihood of 1000 people. The
Pakistan affiliate is also responsible for managing
distribution networks in Afghanistan.
Getz Pharma is a member of the Getz Group of Companies,
founded in 1995 by Getz Brothers and Co. Inc. It employs more
than 5,700 highly qualified people worldwide and has operations in
South Asia, Central Asia, South-East Asia, Asia-Pacific, the Middle
East and Africa
13. Vision and
Mission
Vision:
• To be the most admired
healthcare company in
Pakistan.
Mission:
• To deliver consistently
superior products and
services which
contribute significantly
to improve the quality of
life of consumers.
14. Mission Statement Evaluation
Items Yes/No
Customers Yes
Products Yes
Markets No
Technology No
Concern for Survival, Growth, and Profitability Yes
Philosophy Yes
Self-Concept No
Concern for Public Image No
Concern for Employees No
15. Proposed
Mission
Mission:
• To deliver consistently
superior quality
pharmaceutical and
healthcare products and
services produced under
high equipment facilities
which contribute
significantly to improve
the quality life of
consumers and
protection of
environment.
16. Mission Statement Evaluation
Items Yes/No
Customers Yes
Products Yes
Markets No
Technology Yes
Concern for Survival, Growth, and Profitability Yes
Philosophy Yes
Self-Concept No
Concern for Public Image Yes
Concern for Employees No
17. Internal Strengths And Weaknesses
Strengths:
1. Strong Brand Reputation in Pharma Industry
2. Global Presence
3. Strategic Alliances
4. Diversified variety of Products
5. Experience of 100+ years in Pharma Industry
6. Innovation Leader
Weaknesses:
1. Labor Turnover
2. Recent Expiring Patents
3. Declining Marketing Share
4. Less Focus on Marketing
18. Internal Factor Evaluation (IFE)
Strengths Weight Rating Weighted
Average
Strong Brand Reputation in Pharma Industry 0.2 3 0.6
Global Presence 0.1 2 0.2
Strategic Alliances 0.2 3 0.6
Diversified variety of Products 0.1 3 0.3
Experience of 100+ years in Pharma Industry 0.05 1 0.05
Innovation Leader 0.1 3 0.3
Weaknesses
Labor Turnover 0.07 4 0.28
Recent Expiring Patents 0.06 4 0.24
Declining Marketing Share 0.07 3 0.21
Less Focus on Marketing 0.05 2 0.1
Total 1 2.88
19. External Opportunities And Threats
Opportunities:
1. Expected Growth in Industry
2. Increase in requirement of “Quality of Life”
3. Support From Govt.
4. Increase in consumption of Customers
5. Increasing Technology in Health Care Products
Threats:
1. Entrance of New Multinational Firm
2. Exchange Rate Fluctuation
3. Strict Rules and Regulations
4. Threat of Substitutes like Herbal, and Homeopathic products.
5. Increasing issues of Copy
20. External Factor Evaluation (EFE)
Opportunities Weight Rating Wt. Av.
Expected Growth in Industry 0.05 2 0.1
Increase in requirement of “Quality of Life” 0.1 3 0.3
Support From Govt. 0.05 2 0.1
Increase in consumption of Customers 0.1 3 0.3
Increasing Technology in Health Care Products 0.2 4 0.8
Threats
Entrance of New Multinational Firm 0.15 3 0.45
Exchange Rate Fluctuation 0.12 3 0.36
Strict Rules and Regulations 0.13 3 0.39
Threat of Substitutes, i.e., Herbal, and Homeopathic
products. 0.07 2 0.14
Increasing issues of Copy 0.03 2 0.06
Total 1 3
24. Strengths
Strong Brand Reputation in Pharma
Industry
1.Global Presence
2.Strategic Alliances
3.Diversified variety of Products
4.Experience of 100+ years in
Pharma Industry
5.Innovation Leader
Weaknesses
Labor Turnover
1.Recent Expiring
Patents
2.Declining Marketing
Share
3.Less Focus on
Marketing
Threat
Entrance of New
Multinational Firms
Exchange Rate
Fluctuation
1.Strict Rules &
Regulations
2.Threat of Substitutes
3.Increasing issues of
Copy
Opportunities
Expected Growth in Industry
Increase in requirement of
“Quality of Life”
Support From Govt.
Increase in consumption of
Customers
Increasing Technology in
Health Care Products
SO STRATEGIES
1. Through Strategic Alliance carter
the growth in industry (S3, O1)
2. Expand the distribution to
access the demand for modern
medicines (S3, O4, O5).
WO STRATEGIES
1. Social sites can be used for
promotion & marketing. (W3, W4, O4,
O5).
WT STRATEGIES
1. Focus on Marketing practices will
reduce the threat of substitute and
issues of copy as customers will find
the actual products. W4, T4, T5).
2. Reissue the expired patents with
modifications to overcome the threat
of copying. (W2, T5).
ST STRATEGIES
1. Focus on Innovation and using
strategic alliances will reduce the
threat of entrance of new firms. (S3,
S6, T1).
2. Develop the products that have
minimal side effects to face the
competition from herbal and
homeopathic products. (S1, S5, S6,
T3, T4)
TOWSAnalysis
26. Portor’s 5 Force Analysis
EXISTING MARKET
SCENARIO (High)
Large Industry Size
Strong Competitors
Rapid Growth in Industry
SUPPLIERS (High)
High Level of Competition among
Suppliers
CUSTOMERS
(Low)
Limited Choices
Product is important
Large Number of Buyers
THREATS (NEW ENTRANTS) (Low)
Brand name is important
High Capital and Advance
Technologies are Required
THREAT OF SUBSTITUTE
PRODUCTS (Moderate)
Substitute products are
inferior and slow in reaction
High cost of switching
27.
28. Financial Highlights
Rupees in Million
Total Assets 19,236.30
Total Revenues 26,088.20
Total Liabilities 4,880.40
Shareholders' Equity 14,355.80
Earnings Per Share(PKR) 42.95
Total Assets 17,645.20
Total Revenues 23,387.90
Total Liabilities 3,051.90
Shareholders' Equity 14,593.20
Earnings Per Share(PKR) 41.05
Total Assets 16,488.30
Total Revenues 21,140.40
Total Liabilities 3,539.00
Shareholders' Equity 12,949.20
Earnings Per Share(PKR) 36.56
35. Recommendations
• Company should come up with the
products that have minimal side
effects to stay in the market and
reduce the issue of copy.
• For reducing the employees
turnover, company must focus on
the proper recruitment and
Selection process.
• Government should focus on the
current condition of pharmaceutical
and health care companies to
ensure the health of public.
• Company should focus on the
technological change, i.e.,
innovative technologies, online
presence and e-commerce.